CA2188351C - Filament for irradiating a living body and method for producing a filament for irradiating a living body - Google Patents
Filament for irradiating a living body and method for producing a filament for irradiating a living body Download PDFInfo
- Publication number
- CA2188351C CA2188351C CA002188351A CA2188351A CA2188351C CA 2188351 C CA2188351 C CA 2188351C CA 002188351 A CA002188351 A CA 002188351A CA 2188351 A CA2188351 A CA 2188351A CA 2188351 C CA2188351 C CA 2188351C
- Authority
- CA
- Canada
- Prior art keywords
- core
- casing
- filament
- forming
- atomic percent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
- A61N5/1002—Intraluminal radiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
- A61N2005/1019—Sources therefor
- A61N2005/1025—Wires
Abstract
A filament (1) for irradiating a living body comprises a core (2) of material capable to irradiate radioactive radiation clad in a tubular casing (3) of protective material different from the material farming the core.
The materials forming the core and casing have a purity not less than 99.5 atomic percent and a grain size not exceeding 30 µm and the outer diameter of the filament (1) is not less than 80 µm.
The materials forming the core and casing have a purity not less than 99.5 atomic percent and a grain size not exceeding 30 µm and the outer diameter of the filament (1) is not less than 80 µm.
Description
218~51 -This invention relates to a filament for irradiating a living body, comprising a core of material capable to irradiate radioactive radiation after activation, said core being clad in a casing of protective material, wherein the materials forming the core and casing differ from one another.
The invention also relates to a method for producing a filament for irradiating a living body.
Endoluminal brachytherapy, and more particularly percutaneous transluminal brachytherapy, currently face difficulties for handling the radioactive material, either on a therapeutical viewpoint or on a manufacturing viewpoint. As a matter of fact, it is quite frequent that the structure embodying the radioactive material is bulky and lacks flexibility, whereby the material is difficult to operate through tortuous vessel configurations or narrow passages thereof; this may cause damage or even destruction of the radioactive structure together with the resulting risk of harmful influence on the organism. Furthermore, the radioactive material may enter into direct contact with the vessel walls, which greatly amplifies the risk of unwanted damage to the vessel. And when the radioactive material is merely coated or covered by an outer material, the coating or cover may help protecting the vessel wall from direct contact with the radioactive source, but there is still a substantial danger of having the radioactive material or particles thereof entering into unwanted contact with the vessel wall in case of deterioration of the coating or cover or because the coating or cover still have uncontrolled pores through which the radioactive material may cause damage to the vessel.
218~351 For example, the document WO 93/04735 describes an apparatus for the treatment of an artery, comprising a radioactive dose and means operatively connected to such a dose to bring it into a selected region of an artery.
In one embodiment, the apparatus comprises a wire wound sheath removably positioned over a windowed housing made of a wire winding containing a radioactive dose, whereby relative motion between the sheath and housing permits moving the windowed housing in and out of the sheath to expose the radioactive dose in some place of an artery.
In another embodiment the apparatus comprises a motion wire having 2 radioactive dose affixed at its distal end and a retractable sheath formed of a helisally wound member positiQned over the motion wire and radioactive configuration to provide a measure of shielding to the radioactive dose during insertion and removal of the system into an artery, whereby the sheath may be retracted to expose the radioactive dose at a selected place in the artery. A further embQdiment comprises a shaft portion having at its distal end a canister containing a radioactive dose and provided with a remotely actuated window which can be manipulated to expose the radioactive dose in an injured area of an artery. In a still further embodiment, a plurality of radioactive dose means are encased in a heat shrinkable polymer catheter tip having spacers made of a meltable material to provide encapsulation of the radioactive dose means, which provides flexibility of the apparatus but not longitudinal homogeneity of the radioactive source. In a balloon configuration of the apparatus, radioastive elements are affixed to the outer surface of an angioplasty balloon. In a stent arrangement of the apparatus, the radioactive element may be associated with an expandable stent and it is said that the radioactive means may be included in the stent as a 218~351 , i ~
/ '' !f ~ h~
~ ,i, , 1 cladding, a coating, an additive within the basic stent material, or an attachment by other means to the stent.
As a further example of the aforesaid drawbacks, US
Patent 5, 059,166 describes an intra-arterial stent with the capability to inhibit intimal hyperplasia by means of radioactive radiation. The dQcument refers to a radioisotope integral to an arterial stent which can irradiate the tissue in close proximity to the implantation site of the stent. In one embodiment, a helical coil spring stent is fabricated from a pure metal or alloy which has been activated so that it has become radioactive, i.e., it is a radioisotope; the radioisotope used for this purpose may be an alpha, beta, or gamma emitter, a beta emitter such as Vanadium 48 being preferred because of its short travel in human tissue and 16 days half-life and only 8% of emitted energy from gamma radiation. In another coniguration, the stent spring wire is made from a metal such as steel into which is alloyed an ele~.ent that san be made into a - radioisotope, for example PhosphQrus 32 which is a 14.3 day half-life beta emitter. In a further configuration, the stent wire is made from a radioisotope core material with an outer covering that has the attributes that are desirable for being a coil spring. In a variant, the stent wire is made of a radioisotope coating plated onto a spring material core. Still a further embodiment shows a mQre complex configuratiQn in which a core of some material suited for stents is plated with a radioisotope coating which is in turn coated with an anti-thrombogenic coating such as carbon.
Within the frame of a centering configuration aimed at uniformly applying a radioactive radiation to a vessel wall, the docu~ent EP 0633041 A1 outlines the use of a radioactive emitter in the form of a filament of small di2meter, which may be coiled. Filament technology has the advantage of a dens concentration of the radio2ctive dose in a small volume of the source allowing a reduced diameter and a better manoeuvr2bility in narrow and/or tortuous vessels. In one embodiment, the fil2ment may be made of 89 Yttrium heat elabQrated under vacuum to a di2meter equal to or less th2n 0.2 mm.
In the environment of a medical 2ppli2nce for the treatment of body vessels by ioni~ing r2diation described in Europe2n Patent Application N~ 9~1Q8913.8 filed June 10, 199~ by the applic2nt hereto, the filament technology is enhanced by h2ving a fil2ment, which may be in the form of a coil, coated by a neutral material such as Titanium.
It is 2n object of this invention to improve the conditions of use in a patient 2s well as those of h2ndling the sources llsed for irradiating a living body and more particul2rly those sources used for endolumin21 or percutaneous tr2nslumin21 br2chytherapy. It is a further obiect of the invention to improve such conditions by me2ns of a fil2ment which is highly safe.
Still a further object of the invention is a method for m2nuf2cturing a filament for irr2diating a living body which is fully controll2ble, devoid of haz2rdous technologic21 operations with radio2ctive subst2nces, and which results in a product which practically eliminates the ris~ of h2ving r2dio2ctive core m2terials or particles thereof entering into unw2nted contact with a living body.
To this effect, the invention co~.plies with the definitions given in the claims.
218835~
Acordingly, with the materials forming the core and protective casing having a grain size e~ual to or less than 30 ~m, a filament is achieved which has all the advantages of the filament technology for dens concentration of radioactive dose and for exceptional flexibility and manoeuvrability through narrow and/or tortuQus areas of body vessels. And this is achieved within a configuration in which the core and casing have a great homQgeneity which strongly reduces brittleness of the materials and which practically eliminates any risk of having cracks or ruptures in case of deformation as well as any risk of having radioactive particles wandering through uncontrolled pores of the protective casing. Safe handling of the radioactive core is thus highly effective and there is no danger of unwanted harmful influence of the radioactive material on the organism.
Where the materials forming the core and protective casing have a grain size equal to or less than 10 um, the filament achieves a further degree in terms of isotrQpic lateral flexibility and homogeneQus distribution of the core material throughQut the length of the filament, with a further safety in terms of brittleness reduction of the materials.
Where the materials forming the core and protective casing have a purity of at least 99.5 atomic percent, homogeneity of the filament is still enhanced with the corresponding safety and absence of brittleness. And when the material forming the core is alloyed by 0.1 to 0.3 atomic percent with the material forming the protective casing and the material forming the protective casing alloyed by 0.1 to 0.3 atomic percent with the material forming the core, the strength of the filament is still strongly increased without any loss on 218~Sl the control of the tightness of the materials; the probability of cracks or damage to the assembly is further reduced. With a filament having an outer diameter equal to or over 80 ~m a limit is achieved on the strength of the materials while retaining the aforesaid qualities; a filament of that si~e is specifically suitable for percutaneous transluminal procedures. With the materials forming the core and protective casing having the same crystal lattice, which may be advantageously a hexagonal crystal lattice, high purity and small grain size as well as the mechanical properties and pore control of the assembly are further enhanced.
Preferably, the material forming the core is a beta radiation emitter, and more particularly Yttrium or Thulium, to take advantage of an appreciable irradiation combined to a suitable half-life. This is desirable to allow procedure times that are manageable in interventional medicine such as percutaneous transluminal angioplasty. Moreover, beta emitters such as Yttrium or Thulium have a hexagonal crystal lattice which best fits to the employed casing material. Still preferably, the material forming the protestive casing is Titanium, which has a short half-life and which is biocompatible while having very good mechanical properties providing absence of leakage of the core material. Moreover, the hexagonal crystal lattice of Titanium provides comp2tible deformation properties with the core materials.
The filament may be easily coiled to still further promote the elasticity of the resulting source in case of handling through tortuous vessels without the risk of damage or sracks in the assembly.
21883~1 By the steps of forming an initial billet of core material capable to irradiate radiQactive radiation after activation, forming an initial tubular preform of casing material differing frQm the core material, working said initial billet and tubular preform until they have a grain size equal to or less than 3Q ~m, inserting said billet into said tubular preform to have an assembly, drawing said assembly through a series of successive dies of decreasing size with intermediate annealing of the assembly in intervals between successive dies until the said assembly has a final outer diameter, and end sealing of the casing material Qn the core material, a method for producing a filament is achieved which is fully cQntrollable, allowing decrease of the internal stress and grain size of both the core and casing materials. Each draw se~uence throllgh a die reduces the grain size by fragmentation of the grains and the further recrystallization occurring during the intermediate annealing between successive dies starts a re-crystallization at the reduced grain size. Grow up of the grain is thus avoided; a 10 ~m grain size may be securely achieved and frQm that basis it is readily possible to obtain a 5 to 7 ~m grain size without any risk of uncontrQlled growing up of the grain ~5 size. Final sealing of the casing material on the core material may be made without affecting the structure of the materials. The resulting filament has thus a high homogeneity which reduces its brittleness and avoids the risk of having cracks or ruptures therein under current deformation. The risk of having unwanted radioactive particles wandering through uncontrQlled pores of the filament is practically eliminated.
By the aforesaid method, the assembly cQmprising casing and core materials may be drawn up to an outer diameter equal to or over 80 ~m without affecting the strength of - 21883~i1 the materials and ~ualities of the filament. And the method may comprise the step of coiling the drawn assembly before end sealing of the casing material on the core material, still without affecting their homogeneity and without any risk of cracks or ruptures in the filament.
When the method includes the step of cutting the drawn asse~.bly into a plurality of sub-assemblies before end sealing of the casing material on the core material, whereas end sealing of the casing material on the core material is made on each of said sub-assemblies, filament assemblies may be produced economically in a continuous manner, the assemblies being then cut at will.
Advantageously, end sealing of the casing material on the core material is made by laser welding for a precise procedure.
When the core material and the protective casing material have a purity of at least 99.5 atomic percent, the method still achieves a greater homogeneity for the resulting filament under the same basics of fully controlled manufacture. And to enhance the mechanical properties of the filament while further reducing the probability of cracks or damage, the method may comprise the preliminary step of alloying the core material by O .1 to O . 3 atomic percent with the casing material and alloying the casing material by 0.1 to 0.3 atomic percent with the core material.
To further enhance the technological feasibility of the process the core material and casing material may have the same crystal lattice, preferably a hexagonal crystal ~8~35 1 lattice which will fit best with compatible strength, plasticity and annealing temperatures.
When the method further comprises the step of activating the core material in the casing material in a nuclear reactor, activation is made at the final stage of production of the filament, which is easier and suhstantially reduces the manipulations of radioactive filament. The resulting CQSt is lower and the risks of contamination are strongly limited.
These and other ohjects and features of the invention will become readily apparent from the following detailed description with reference to the accompanying drawings which illustrate, diagrammatically and by way Qf example only, two embodiments of a filament according to the invention.
Figure 1 is an axial cut of a filament according to the first embQdiment;
Figure 2 is a cross section according to line I-I of Figure 1;
Figure 3 is an axial view, partly cut, of a radiation sQurce formed of a soiled filament according to the second embodiment.
The filament 1 shown in Figure 1 comprises a core 2 of material capable to irradiate radioactive radiation.
Preferably, the core 1 is made of a cylindrical wire of a beta radiation emitter such as Yttrium or Thulium having a purity of 99,5 atomic percent. Yttrium and Thulium both have a hexagonal crystal lattice and a relatively small grain size.
21883~1 The core 2 is clad in a tubular casing 3 of protective material different from the material of the core.
Preferably, the casing 3 is made of Titanium having a purity of 99,5 atomic percent, preferably 99.~ atomic percent. Titanium also has a hexagonal crystal lattice with a relatively small grain size.
The materials, Yttrium and Thulium, resp. Titanium, forming the core 2 and protective casing 3 have a grain size not exceeding 30 ~m, preferably equal to or less than 10 ~m. The outer diameter of the filament 1 is not less than 80 ~m.
Advantageously, the production of the filament 1 may he obtained by forming an initial billet of core material and an initial tubular preform of casing material differing from the core material. Such billet and tubular preform are worked, for instance by deformation and thermal treatment or as ingots and serial consequent hot drawing, until they have a grain size equal to or less than 30 ~m. The billet is then inserted into the tubular preform to form an assembly which is drawn through a series of successive dies of decreasing size.
In intervals between successive dies, the drawn assembly ~5 is allowed to anneal, which process provides a decrease in internal stress and allows formation of a small grain structure of the core and casing materials less than 30 ~m. The casing is then hermetically sealed on the core 2, preferably by taking off by etching a portion of the Yttrium or Thulium wire at its ends a, and thereafter closing the ends 5 of the Titanium tube 3 into a smooth spherical tip which does not substantially exceed the outer surface at the filament 1. For example, this procedure may be achieved by means of spot laser welding. After completion of this assembly, the filament 218~35i may be brought into a nuclear reactor (not shown) for activation of the core 2 in the casing 3.
According to a variant, the material forming the core 2 may be alloyed by 0.1 to 0.3 atomic percent of the material forming the casing 3 with the material fQrming the casing 3 alloyed by 0.1 to 0.3 atomic percent of the material forming the core 2. The manufacturing process follows then as described hereabove.
The filament 5 shown in Figure 3 is made identically as and with the same integers ~bearing the same reference numerals) as the filament 1 of Figure 1 or its alloyed variant. After completion of the assembly of core 2 and casing 3, the filament 6 is applied on a mandrel (not shown) in order to be formed as a coil 7 and then end sealing of the casing material on the core material is made as described hereabove. After cQmpletion of the assembly forming the fila~ent 5 and its coil shaping 7 and sealing, the filament may be brought into a nuclear reactor for activation of the core 2 in the casing 3.
Variants are available. For instancet instead of Yttrium or Thulium, other emitters may be used for the coré 2, more particularly ~uropium or Gadolinium or Terbium which al~o have a hexagonal crystal lattice. It is also possible to use other metals such as Platinum or Gold or Silver instead of Titanium for forming the casing, although such metals have a cubical crystal lattice.
Such potential coverage materials could be preferably used with Iridium, Caesium or other core materials having a cubic crystal lattice.
The filament as shown in Figures 1 and 2 may be used as such or affixed at the end of a guiding structure or of a guide wire as used in endoluminal or transluminal 21~8~5 1 brachytherapy, or 2S a wire to partly or completely form or make part of a stent, in which case energizatiQn in the nuclear reactor will be made after sompletion of the stent structure.
The invention also relates to a method for producing a filament for irradiating a living body.
Endoluminal brachytherapy, and more particularly percutaneous transluminal brachytherapy, currently face difficulties for handling the radioactive material, either on a therapeutical viewpoint or on a manufacturing viewpoint. As a matter of fact, it is quite frequent that the structure embodying the radioactive material is bulky and lacks flexibility, whereby the material is difficult to operate through tortuous vessel configurations or narrow passages thereof; this may cause damage or even destruction of the radioactive structure together with the resulting risk of harmful influence on the organism. Furthermore, the radioactive material may enter into direct contact with the vessel walls, which greatly amplifies the risk of unwanted damage to the vessel. And when the radioactive material is merely coated or covered by an outer material, the coating or cover may help protecting the vessel wall from direct contact with the radioactive source, but there is still a substantial danger of having the radioactive material or particles thereof entering into unwanted contact with the vessel wall in case of deterioration of the coating or cover or because the coating or cover still have uncontrolled pores through which the radioactive material may cause damage to the vessel.
218~351 For example, the document WO 93/04735 describes an apparatus for the treatment of an artery, comprising a radioactive dose and means operatively connected to such a dose to bring it into a selected region of an artery.
In one embodiment, the apparatus comprises a wire wound sheath removably positioned over a windowed housing made of a wire winding containing a radioactive dose, whereby relative motion between the sheath and housing permits moving the windowed housing in and out of the sheath to expose the radioactive dose in some place of an artery.
In another embodiment the apparatus comprises a motion wire having 2 radioactive dose affixed at its distal end and a retractable sheath formed of a helisally wound member positiQned over the motion wire and radioactive configuration to provide a measure of shielding to the radioactive dose during insertion and removal of the system into an artery, whereby the sheath may be retracted to expose the radioactive dose at a selected place in the artery. A further embQdiment comprises a shaft portion having at its distal end a canister containing a radioactive dose and provided with a remotely actuated window which can be manipulated to expose the radioactive dose in an injured area of an artery. In a still further embodiment, a plurality of radioactive dose means are encased in a heat shrinkable polymer catheter tip having spacers made of a meltable material to provide encapsulation of the radioactive dose means, which provides flexibility of the apparatus but not longitudinal homogeneity of the radioactive source. In a balloon configuration of the apparatus, radioastive elements are affixed to the outer surface of an angioplasty balloon. In a stent arrangement of the apparatus, the radioactive element may be associated with an expandable stent and it is said that the radioactive means may be included in the stent as a 218~351 , i ~
/ '' !f ~ h~
~ ,i, , 1 cladding, a coating, an additive within the basic stent material, or an attachment by other means to the stent.
As a further example of the aforesaid drawbacks, US
Patent 5, 059,166 describes an intra-arterial stent with the capability to inhibit intimal hyperplasia by means of radioactive radiation. The dQcument refers to a radioisotope integral to an arterial stent which can irradiate the tissue in close proximity to the implantation site of the stent. In one embodiment, a helical coil spring stent is fabricated from a pure metal or alloy which has been activated so that it has become radioactive, i.e., it is a radioisotope; the radioisotope used for this purpose may be an alpha, beta, or gamma emitter, a beta emitter such as Vanadium 48 being preferred because of its short travel in human tissue and 16 days half-life and only 8% of emitted energy from gamma radiation. In another coniguration, the stent spring wire is made from a metal such as steel into which is alloyed an ele~.ent that san be made into a - radioisotope, for example PhosphQrus 32 which is a 14.3 day half-life beta emitter. In a further configuration, the stent wire is made from a radioisotope core material with an outer covering that has the attributes that are desirable for being a coil spring. In a variant, the stent wire is made of a radioisotope coating plated onto a spring material core. Still a further embodiment shows a mQre complex configuratiQn in which a core of some material suited for stents is plated with a radioisotope coating which is in turn coated with an anti-thrombogenic coating such as carbon.
Within the frame of a centering configuration aimed at uniformly applying a radioactive radiation to a vessel wall, the docu~ent EP 0633041 A1 outlines the use of a radioactive emitter in the form of a filament of small di2meter, which may be coiled. Filament technology has the advantage of a dens concentration of the radio2ctive dose in a small volume of the source allowing a reduced diameter and a better manoeuvr2bility in narrow and/or tortuous vessels. In one embodiment, the fil2ment may be made of 89 Yttrium heat elabQrated under vacuum to a di2meter equal to or less th2n 0.2 mm.
In the environment of a medical 2ppli2nce for the treatment of body vessels by ioni~ing r2diation described in Europe2n Patent Application N~ 9~1Q8913.8 filed June 10, 199~ by the applic2nt hereto, the filament technology is enhanced by h2ving a fil2ment, which may be in the form of a coil, coated by a neutral material such as Titanium.
It is 2n object of this invention to improve the conditions of use in a patient 2s well as those of h2ndling the sources llsed for irradiating a living body and more particul2rly those sources used for endolumin21 or percutaneous tr2nslumin21 br2chytherapy. It is a further obiect of the invention to improve such conditions by me2ns of a fil2ment which is highly safe.
Still a further object of the invention is a method for m2nuf2cturing a filament for irr2diating a living body which is fully controll2ble, devoid of haz2rdous technologic21 operations with radio2ctive subst2nces, and which results in a product which practically eliminates the ris~ of h2ving r2dio2ctive core m2terials or particles thereof entering into unw2nted contact with a living body.
To this effect, the invention co~.plies with the definitions given in the claims.
218835~
Acordingly, with the materials forming the core and protective casing having a grain size e~ual to or less than 30 ~m, a filament is achieved which has all the advantages of the filament technology for dens concentration of radioactive dose and for exceptional flexibility and manoeuvrability through narrow and/or tortuQus areas of body vessels. And this is achieved within a configuration in which the core and casing have a great homQgeneity which strongly reduces brittleness of the materials and which practically eliminates any risk of having cracks or ruptures in case of deformation as well as any risk of having radioactive particles wandering through uncontrolled pores of the protective casing. Safe handling of the radioactive core is thus highly effective and there is no danger of unwanted harmful influence of the radioactive material on the organism.
Where the materials forming the core and protective casing have a grain size equal to or less than 10 um, the filament achieves a further degree in terms of isotrQpic lateral flexibility and homogeneQus distribution of the core material throughQut the length of the filament, with a further safety in terms of brittleness reduction of the materials.
Where the materials forming the core and protective casing have a purity of at least 99.5 atomic percent, homogeneity of the filament is still enhanced with the corresponding safety and absence of brittleness. And when the material forming the core is alloyed by 0.1 to 0.3 atomic percent with the material forming the protective casing and the material forming the protective casing alloyed by 0.1 to 0.3 atomic percent with the material forming the core, the strength of the filament is still strongly increased without any loss on 218~Sl the control of the tightness of the materials; the probability of cracks or damage to the assembly is further reduced. With a filament having an outer diameter equal to or over 80 ~m a limit is achieved on the strength of the materials while retaining the aforesaid qualities; a filament of that si~e is specifically suitable for percutaneous transluminal procedures. With the materials forming the core and protective casing having the same crystal lattice, which may be advantageously a hexagonal crystal lattice, high purity and small grain size as well as the mechanical properties and pore control of the assembly are further enhanced.
Preferably, the material forming the core is a beta radiation emitter, and more particularly Yttrium or Thulium, to take advantage of an appreciable irradiation combined to a suitable half-life. This is desirable to allow procedure times that are manageable in interventional medicine such as percutaneous transluminal angioplasty. Moreover, beta emitters such as Yttrium or Thulium have a hexagonal crystal lattice which best fits to the employed casing material. Still preferably, the material forming the protestive casing is Titanium, which has a short half-life and which is biocompatible while having very good mechanical properties providing absence of leakage of the core material. Moreover, the hexagonal crystal lattice of Titanium provides comp2tible deformation properties with the core materials.
The filament may be easily coiled to still further promote the elasticity of the resulting source in case of handling through tortuous vessels without the risk of damage or sracks in the assembly.
21883~1 By the steps of forming an initial billet of core material capable to irradiate radiQactive radiation after activation, forming an initial tubular preform of casing material differing frQm the core material, working said initial billet and tubular preform until they have a grain size equal to or less than 3Q ~m, inserting said billet into said tubular preform to have an assembly, drawing said assembly through a series of successive dies of decreasing size with intermediate annealing of the assembly in intervals between successive dies until the said assembly has a final outer diameter, and end sealing of the casing material Qn the core material, a method for producing a filament is achieved which is fully cQntrollable, allowing decrease of the internal stress and grain size of both the core and casing materials. Each draw se~uence throllgh a die reduces the grain size by fragmentation of the grains and the further recrystallization occurring during the intermediate annealing between successive dies starts a re-crystallization at the reduced grain size. Grow up of the grain is thus avoided; a 10 ~m grain size may be securely achieved and frQm that basis it is readily possible to obtain a 5 to 7 ~m grain size without any risk of uncontrQlled growing up of the grain ~5 size. Final sealing of the casing material on the core material may be made without affecting the structure of the materials. The resulting filament has thus a high homogeneity which reduces its brittleness and avoids the risk of having cracks or ruptures therein under current deformation. The risk of having unwanted radioactive particles wandering through uncontrQlled pores of the filament is practically eliminated.
By the aforesaid method, the assembly cQmprising casing and core materials may be drawn up to an outer diameter equal to or over 80 ~m without affecting the strength of - 21883~i1 the materials and ~ualities of the filament. And the method may comprise the step of coiling the drawn assembly before end sealing of the casing material on the core material, still without affecting their homogeneity and without any risk of cracks or ruptures in the filament.
When the method includes the step of cutting the drawn asse~.bly into a plurality of sub-assemblies before end sealing of the casing material on the core material, whereas end sealing of the casing material on the core material is made on each of said sub-assemblies, filament assemblies may be produced economically in a continuous manner, the assemblies being then cut at will.
Advantageously, end sealing of the casing material on the core material is made by laser welding for a precise procedure.
When the core material and the protective casing material have a purity of at least 99.5 atomic percent, the method still achieves a greater homogeneity for the resulting filament under the same basics of fully controlled manufacture. And to enhance the mechanical properties of the filament while further reducing the probability of cracks or damage, the method may comprise the preliminary step of alloying the core material by O .1 to O . 3 atomic percent with the casing material and alloying the casing material by 0.1 to 0.3 atomic percent with the core material.
To further enhance the technological feasibility of the process the core material and casing material may have the same crystal lattice, preferably a hexagonal crystal ~8~35 1 lattice which will fit best with compatible strength, plasticity and annealing temperatures.
When the method further comprises the step of activating the core material in the casing material in a nuclear reactor, activation is made at the final stage of production of the filament, which is easier and suhstantially reduces the manipulations of radioactive filament. The resulting CQSt is lower and the risks of contamination are strongly limited.
These and other ohjects and features of the invention will become readily apparent from the following detailed description with reference to the accompanying drawings which illustrate, diagrammatically and by way Qf example only, two embodiments of a filament according to the invention.
Figure 1 is an axial cut of a filament according to the first embQdiment;
Figure 2 is a cross section according to line I-I of Figure 1;
Figure 3 is an axial view, partly cut, of a radiation sQurce formed of a soiled filament according to the second embodiment.
The filament 1 shown in Figure 1 comprises a core 2 of material capable to irradiate radioactive radiation.
Preferably, the core 1 is made of a cylindrical wire of a beta radiation emitter such as Yttrium or Thulium having a purity of 99,5 atomic percent. Yttrium and Thulium both have a hexagonal crystal lattice and a relatively small grain size.
21883~1 The core 2 is clad in a tubular casing 3 of protective material different from the material of the core.
Preferably, the casing 3 is made of Titanium having a purity of 99,5 atomic percent, preferably 99.~ atomic percent. Titanium also has a hexagonal crystal lattice with a relatively small grain size.
The materials, Yttrium and Thulium, resp. Titanium, forming the core 2 and protective casing 3 have a grain size not exceeding 30 ~m, preferably equal to or less than 10 ~m. The outer diameter of the filament 1 is not less than 80 ~m.
Advantageously, the production of the filament 1 may he obtained by forming an initial billet of core material and an initial tubular preform of casing material differing from the core material. Such billet and tubular preform are worked, for instance by deformation and thermal treatment or as ingots and serial consequent hot drawing, until they have a grain size equal to or less than 30 ~m. The billet is then inserted into the tubular preform to form an assembly which is drawn through a series of successive dies of decreasing size.
In intervals between successive dies, the drawn assembly ~5 is allowed to anneal, which process provides a decrease in internal stress and allows formation of a small grain structure of the core and casing materials less than 30 ~m. The casing is then hermetically sealed on the core 2, preferably by taking off by etching a portion of the Yttrium or Thulium wire at its ends a, and thereafter closing the ends 5 of the Titanium tube 3 into a smooth spherical tip which does not substantially exceed the outer surface at the filament 1. For example, this procedure may be achieved by means of spot laser welding. After completion of this assembly, the filament 218~35i may be brought into a nuclear reactor (not shown) for activation of the core 2 in the casing 3.
According to a variant, the material forming the core 2 may be alloyed by 0.1 to 0.3 atomic percent of the material forming the casing 3 with the material fQrming the casing 3 alloyed by 0.1 to 0.3 atomic percent of the material forming the core 2. The manufacturing process follows then as described hereabove.
The filament 5 shown in Figure 3 is made identically as and with the same integers ~bearing the same reference numerals) as the filament 1 of Figure 1 or its alloyed variant. After completion of the assembly of core 2 and casing 3, the filament 6 is applied on a mandrel (not shown) in order to be formed as a coil 7 and then end sealing of the casing material on the core material is made as described hereabove. After cQmpletion of the assembly forming the fila~ent 5 and its coil shaping 7 and sealing, the filament may be brought into a nuclear reactor for activation of the core 2 in the casing 3.
Variants are available. For instancet instead of Yttrium or Thulium, other emitters may be used for the coré 2, more particularly ~uropium or Gadolinium or Terbium which al~o have a hexagonal crystal lattice. It is also possible to use other metals such as Platinum or Gold or Silver instead of Titanium for forming the casing, although such metals have a cubical crystal lattice.
Such potential coverage materials could be preferably used with Iridium, Caesium or other core materials having a cubic crystal lattice.
The filament as shown in Figures 1 and 2 may be used as such or affixed at the end of a guiding structure or of a guide wire as used in endoluminal or transluminal 21~8~5 1 brachytherapy, or 2S a wire to partly or completely form or make part of a stent, in which case energizatiQn in the nuclear reactor will be made after sompletion of the stent structure.
Claims (26)
1. A filament (1,6) for irradiating a living body, comprising a core (2) of material capable to irradiate radioactive radiation after activation, said core being clad in a casing (3) of protective material, wherein the materials farming the core (2) and casing (3) differ from one another, characterized in that the materials forming the core (2) and protective casing (3) have a grain size equal to or less than 30 µm.
2. A filament according to claim 1, wherein the materials forming the core (2) and protective casing (3) have a grain size equal to or less than 10 µm.
3. A filament according to claim 1 or 2, wherein the materials forming the core (2) and protective casing (3) have a purity of at least 99.5 atomic percent.
4. A filament according to any of Claims 1 to 3, wherein the material forming the core (2) is alloyed by 0.1 to 0.3 atomic percent with the material forming the protective casing (3), and the material forming the protective casing (3) is alloyed by 0.1 to 0.3 atomic percent with the material forming the core (2).
5. A filament according to any one of claims 1 to 4, having an outer diameter equal to or over 80 µm.
6. A filament according to any one of claims 1 to 5, wherein the materials forming the core (2) and protective casing (3) have the same crystal lattice.
7. A filament according to claim 6, wherein the materials forming the core (2) and protective casing (3) have a hexagonal crystal lattice.
8. A filament according to any one of claims 1 to 7, wherein the material forming the core (2) is a beta radiation emitter.
9. A filament according to claim 8, wherein the material forming the core (2) is Yttrium.
10. A filament according to claim 8, wherein the material forming the core (2) is Thulium.
11. A filament according to any one of claims 1 to 10, wherein the material forming the protective casing (3) is Titanium.
12. A filament according to any one of claims 1 to 11, which forms a coil (7).
13. A method producing a filament for irradiating a living body, characterized by the steps:
- forming an initial billet of cors material capable to irradiate radioactive radiation after activation;
- forming an initial tubular preform of casing material differing from said core material;
- working said initial billet and tubular preform until they have a grain size equal to or less than 30 µm;
- inserting said billet into said tubular preform to form an assembly;
- drawing said assembly through a series of successive dies of decreasing size with intermediate annealing of the said assembly and intervals between successive dies until said assembly has a final outer diameter; and - end sealing of the casing material on the core material.
- forming an initial billet of cors material capable to irradiate radioactive radiation after activation;
- forming an initial tubular preform of casing material differing from said core material;
- working said initial billet and tubular preform until they have a grain size equal to or less than 30 µm;
- inserting said billet into said tubular preform to form an assembly;
- drawing said assembly through a series of successive dies of decreasing size with intermediate annealing of the said assembly and intervals between successive dies until said assembly has a final outer diameter; and - end sealing of the casing material on the core material.
14. A method according to claim 13, wherein said final outer diameter is equal to or over 80 µm.
15. A method according to claim 13 or 14, wherein said drawn assembly is coiled before end sealing of the casing material on the core material.
16. A method according to any of claims 13 to 15, wherein said drawn assembly is cut into a plurality of sub-assemblies before end sealing of the casing material on the core material, whereas end sealing of the casing material on the core material is made on each of said sub-assemblies.
17. A method according to any of claims 13 to 15, wherein end sealing of the casing material on the core material is made by spot laser welding.
18. A method according to any of claims 13 to 17, wherein the core material and the protective casing material have a purity of at l east 99.5 atomic percent.
19. A method according to any of claims 13 to 18, comprising the preliminary step of alloying the core material by 0.1 to 0.3 atomic percent with the casing material and alloying the casing material by 0.1 to 0.3 atomic percent with the core material.
20. A method according to any of claims 13 to 19, wherein the core material and the casing material have the same crystal lattice.
21. A method according to any of claims 13 to 20, wherein the core material and the casing material have a hexagonal crystal lattice.
22. A method according to any of claims 13 to 21, wherein the core material is a beta radiation emitter.
23. A method according to claim 22, wherein the core material is Yttrium.
24. A method according to claim 22, wherein the core material is Thulium.
25. A method according to any of claims 13 to 24, wherein the casing material is Titanium.
26. A method according to any of claims 13 to 25, further comprising the step of activating the core material in the casing material in a nuclear reactor.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP95119124A EP0778051B1 (en) | 1995-12-05 | 1995-12-05 | Filament for irradiating a living body and method for producing a filament for irradiating a living body |
| EP95119124.6 | 1995-12-05 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2188351A1 CA2188351A1 (en) | 1997-06-06 |
| CA2188351C true CA2188351C (en) | 2001-01-23 |
Family
ID=8219865
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002188351A Expired - Fee Related CA2188351C (en) | 1995-12-05 | 1996-10-21 | Filament for irradiating a living body and method for producing a filament for irradiating a living body |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US6146322A (en) |
| EP (1) | EP0778051B1 (en) |
| JP (1) | JP3188896B2 (en) |
| AT (1) | ATE236683T1 (en) |
| AU (1) | AU700595B2 (en) |
| CA (1) | CA2188351C (en) |
| DE (1) | DE69530302T2 (en) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0813894B1 (en) | 1993-07-01 | 2001-12-05 | Schneider (Europe) GmbH | Medical appliances for the treatment of blood vessels by means of ionizing radiation |
| ATE170708T1 (en) | 1994-06-10 | 1998-09-15 | Schneider Europ Gmbh | MEDICINAL DEVICE FOR THE TREATMENT OF A PART OF BODY VESSEL USING IONIZATION RADIATION |
| EP0688580B1 (en) | 1994-06-24 | 2000-10-04 | Schneider (Europe) GmbH | Medical appliance for the treatment of a portion of body vessel by ionising radiation |
| US6234951B1 (en) | 1996-02-29 | 2001-05-22 | Scimed Life Systems, Inc. | Intravascular radiation delivery system |
| US5855546A (en) | 1996-02-29 | 1999-01-05 | Sci-Med Life Systems | Perfusion balloon and radioactive wire delivery system |
| IT1291001B1 (en) * | 1997-01-09 | 1998-12-14 | Sorin Biomedica Cardio Spa | ANGIOPLASTIC STENT AND ITS PRODUCTION PROCESS |
| US6676590B1 (en) | 1997-03-06 | 2004-01-13 | Scimed Life Systems, Inc. | Catheter system having tubular radiation source |
| US6019718A (en) | 1997-05-30 | 2000-02-01 | Scimed Life Systems, Inc. | Apparatus for intravascular radioactive treatment |
| US6413203B1 (en) | 1998-09-16 | 2002-07-02 | Scimed Life Systems, Inc. | Method and apparatus for positioning radioactive fluids within a body lumen |
| US6354989B1 (en) | 1998-10-14 | 2002-03-12 | Terumo Kabushiki Kaisha | Radiation source delivery wire and catheter assembly for radiation therapy provided with the same |
| DE69816300T2 (en) | 1998-10-30 | 2004-05-27 | Acrostak Co. | Process for producing a wound body for radioactive radiation |
| SE523926C2 (en) * | 1999-06-15 | 2004-06-01 | Hans Lundqvist | stent Events |
| DE69915287T2 (en) * | 1999-09-20 | 2004-07-22 | Aea Technology Qsa Gmbh | Wire-shaped radiation source for endovascular radiation |
| US6398709B1 (en) | 1999-10-19 | 2002-06-04 | Scimed Life Systems, Inc. | Elongated member for intravascular delivery of radiation |
| CA2398832A1 (en) | 1999-11-09 | 2002-08-12 | Forschungszentrum Karlsruhe Gmbh | Mixture containing rare earths and use thereof |
| US6416457B1 (en) | 2000-03-09 | 2002-07-09 | Scimed Life Systems, Inc. | System and method for intravascular ionizing tandem radiation therapy |
| US6416492B1 (en) | 2000-09-28 | 2002-07-09 | Scimed Life Systems, Inc. | Radiation delivery system utilizing intravascular ultrasound |
| US6875165B2 (en) | 2001-02-22 | 2005-04-05 | Retinalabs, Inc. | Method of radiation delivery to the eye |
| US6669621B2 (en) * | 2001-03-14 | 2003-12-30 | Cordis Corporation | Method and assembly for containing radioactive materials |
| US6723052B2 (en) * | 2001-06-07 | 2004-04-20 | Stanley L. Mills | Echogenic medical device |
| IL147898A (en) * | 2002-01-30 | 2007-05-15 | Yuval Golan | Auger effect-based cancer therapy method |
| US7041047B2 (en) | 2002-10-04 | 2006-05-09 | Boston Scientific Scimed, Inc. | Method and apparatus for the delivery of brachytherapy |
| US7435255B1 (en) | 2002-11-13 | 2008-10-14 | Advnaced Cardiovascular Systems, Inc. | Drug-eluting stent and methods of making |
| US7144422B1 (en) * | 2002-11-13 | 2006-12-05 | Advanced Cardiovascular Systems, Inc. | Drug-eluting stent and methods of making the same |
| US7105018B1 (en) * | 2002-12-30 | 2006-09-12 | Advanced Cardiovascular Systems, Inc. | Drug-eluting stent cover and method of use |
| AU2005214040B2 (en) | 2004-02-12 | 2011-03-31 | Neo Vista, Inc. | Methods and apparatus for intraocular brachytherapy |
| CA2629648A1 (en) | 2005-11-15 | 2007-05-24 | Neovista Inc. | Methods and apparatus for intraocular brachytherapy |
| EP2296756A1 (en) | 2008-06-04 | 2011-03-23 | Neovista, Inc. | Handheld radiation delivery system for advancing a radiation source wire |
| US10293553B2 (en) | 2009-10-15 | 2019-05-21 | Covidien Lp | Buttress brachytherapy and integrated staple line markers for margin identification |
| US20150231409A1 (en) | 2009-10-15 | 2015-08-20 | Covidien Lp | Buttress brachytherapy and integrated staple line markers for margin identification |
| US10159850B2 (en) | 2016-01-06 | 2018-12-25 | Covidien Lp | Brachytherapy clip and applicator |
| US11504546B2 (en) | 2019-02-28 | 2022-11-22 | Cowles Ventures, Llc | Needle guidance device for brachytherapy and method of use |
| US11524176B2 (en) | 2019-03-14 | 2022-12-13 | Cowles Ventures, Llc | Locator for placement of fiducial support device method |
| US11224761B1 (en) | 2019-11-19 | 2022-01-18 | Pointsource Technologies, Llc | Radioactive therapeutic device |
Family Cites Families (141)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1442051A (en) * | 1921-05-10 | 1923-01-16 | William L Cummings | Radium needle |
| US2546761A (en) * | 1950-01-13 | 1951-03-27 | Radium Chemical Company Inc | Radium nasopharyngeal applicator |
| GB725067A (en) * | 1952-07-02 | 1955-03-02 | Asea Ab | A device for containing and exposing a radioactive material |
| DE944988C (en) | 1953-03-26 | 1957-05-29 | Dr Med Karl Heinz Rummert | Device for beta or gamma irradiation of body cavities |
| US2955208A (en) * | 1955-05-10 | 1960-10-04 | Technical Operations Inc | Radiographic device |
| US3060924A (en) * | 1960-06-01 | 1962-10-30 | Joseph C Rush | Apparatus for application of radioactive substance to pelvic cancer |
| US3147383A (en) * | 1962-05-16 | 1964-09-01 | Technical Operations Inc | Apparatus for manipulating radioactive material to and from a storage chamber |
| US3324847A (en) * | 1964-06-01 | 1967-06-13 | Elias G Zoumboulis | Radioactive catheter |
| US3505991A (en) * | 1968-02-13 | 1970-04-14 | Us Air Force | Intracorporeal vascular prosthetic blood irradiator |
| SE318971B (en) * | 1968-05-02 | 1969-12-22 | Atomenergi Ab | |
| US3643096A (en) * | 1969-02-27 | 1972-02-15 | Gen Nuclear Inc | Radioactive source shield with safe position indicator |
| FR2033653A5 (en) * | 1969-02-28 | 1970-12-04 | Commissariat Energie Atomique | |
| DE1945015A1 (en) * | 1969-09-05 | 1971-03-11 | Kurt Dr Sauerwein | Device for medical treatment with radiation from radioactive substances |
| US3750653A (en) * | 1970-09-08 | 1973-08-07 | School Of Medicine University | Irradiators for treating the body |
| CA980022A (en) * | 1972-05-15 | 1975-12-16 | Douglas Whitfield | Remotely controlled brachytherapy unit |
| US3811426A (en) * | 1973-05-21 | 1974-05-21 | Atomic Energy Commission | Method and apparatus for the in-vessel radiation treatment of blood |
| US3927325A (en) * | 1974-07-10 | 1975-12-16 | Us Energy | Tissue irradiator |
| US3970073A (en) * | 1975-01-30 | 1976-07-20 | Howlin Enterprises, Inc. | Positioning device for radiation treatment of cervical carcinoma |
| US4096862A (en) * | 1976-05-17 | 1978-06-27 | Deluca Salvatore A | Locating of tubes in the human body |
| DE2727359C2 (en) * | 1977-06-16 | 1986-02-20 | Sauerwein, Kurt, Dr., 5657 Haan | Radiography machine with radiator capsule |
| US4588395A (en) * | 1978-03-10 | 1986-05-13 | Lemelson Jerome H | Catheter and method |
| US4281252A (en) * | 1978-11-27 | 1981-07-28 | Technical Operations, Inc. | Coupling apparatus for portable radiography systems |
| US4225790A (en) * | 1978-11-27 | 1980-09-30 | Technical Operations, Incorporated | Storage reel assembly |
| US4244357A (en) * | 1979-01-05 | 1981-01-13 | Morrison Richard A | Method and apparatus for homogeneously irradiating the vaginal mucosa with a linear source uterovaginal applicator |
| US4314157A (en) * | 1979-06-21 | 1982-02-02 | Industrial Nuclear Company, Inc. | Safety lock for radiography exposure device |
| US4364376A (en) * | 1979-12-26 | 1982-12-21 | Bigham Keith E | Method and device for injecting a bolus of material into a body |
| US4402308A (en) * | 1980-11-03 | 1983-09-06 | Scott Walter P | Medical implantation device |
| DE3335438C2 (en) * | 1983-09-30 | 1985-09-05 | Sauerwein, Kurt, Dr., 5657 Haan | Radiation treatment device |
| US4584991A (en) * | 1983-12-15 | 1986-04-29 | Tokita Kenneth M | Medical device for applying therapeutic radiation |
| EP0165993A1 (en) * | 1983-12-27 | 1986-01-02 | The Board Of Trustees Of The Leland Stanford Junior University | Catheter for treatment of tumors and method for using same |
| NL8400108A (en) * | 1984-01-12 | 1985-08-01 | Hooft Eric T | METHOD AND APPARATUS FOR TREATING A BODY PART WITH RADIOACTIVE MATERIAL |
| US4697575A (en) * | 1984-11-21 | 1987-10-06 | Henry Ford Hospital | Delivery system for interstitial radiation therapy including substantially non-deflecting elongated member |
| DE3442762A1 (en) * | 1984-11-23 | 1986-06-26 | Anwer Dipl.-Ing. 8520 Erlangen Puthawala | REMOTE CONTROLLED AFTERLOADING DEVICE FOR BRACHYCURIE THERAPY OF TUMORS |
| US4702228A (en) * | 1985-01-24 | 1987-10-27 | Theragenics Corporation | X-ray-emitting interstitial implants |
| US5322499A (en) * | 1985-09-20 | 1994-06-21 | Liprie Sam F | Continuous sheated low dose radioactive core adapted for cutting into short sealed segments |
| US5141487A (en) * | 1985-09-20 | 1992-08-25 | Liprie Sam F | Attachment of radioactive source and guidewire in a branchy therapy source wire |
| US4706652A (en) * | 1985-12-30 | 1987-11-17 | Henry Ford Hospital | Temporary radiation therapy |
| US4763642A (en) * | 1986-04-07 | 1988-08-16 | Horowitz Bruce S | Intracavitational brachytherapy |
| NL8601808A (en) * | 1986-07-10 | 1988-02-01 | Hooft Eric T | METHOD FOR TREATING A BODY PART WITH RADIOACTIVE MATERIAL AND CART USED THEREIN |
| US4819618A (en) * | 1986-08-18 | 1989-04-11 | Liprie Sam F | Iridium/platinum implant, method of encapsulation, and method of implantation |
| US4976266A (en) * | 1986-08-29 | 1990-12-11 | United States Department Of Energy | Methods of in vivo radiation measurement |
| FR2609898B1 (en) * | 1987-01-28 | 1989-03-31 | Commissariat Energie Atomique | DEVICE FOR DRIVING AND POSITIONING A SOURCE HOLDER IN AN APPLICATOR USED IN CURIETHERAPY |
| JPS6446056U (en) * | 1987-09-17 | 1989-03-22 | ||
| DE3731946A1 (en) * | 1987-09-23 | 1989-04-13 | Kurt Dr Sauerwein | MAGNETIC COUPLING |
| US4936823A (en) * | 1988-05-04 | 1990-06-26 | Triangle Research And Development Corp. | Transendoscopic implant capsule |
| US5242437A (en) * | 1988-06-10 | 1993-09-07 | Trimedyne Laser Systems, Inc. | Medical device applying localized high intensity light and heat, particularly for destruction of the endometrium |
| US4994013A (en) * | 1988-07-28 | 1991-02-19 | Best Industries, Inc. | Pellet for a radioactive seed |
| US5084002A (en) * | 1988-08-04 | 1992-01-28 | Omnitron International, Inc. | Ultra-thin high dose iridium source for remote afterloader |
| US5092877A (en) * | 1988-09-01 | 1992-03-03 | Corvita Corporation | Radially expandable endoprosthesis |
| US4976680A (en) * | 1988-10-07 | 1990-12-11 | Hayman Michael H | Apparatus for in situ radiotherapy |
| US5103395A (en) * | 1988-10-07 | 1992-04-07 | Spako David W | System for remote positioning of a radioactive source into a patient including means for protection against improper patient exposure to radiation |
| US5183455A (en) * | 1988-10-07 | 1993-02-02 | Omnitron International, Inc. | Apparatus for in situ radiotherapy |
| US4861520A (en) * | 1988-10-28 | 1989-08-29 | Eric van't Hooft | Capsule for radioactive source |
| US4969863A (en) * | 1988-10-28 | 1990-11-13 | Eric van't Hooft | Adaptor for remote after-loading apparatus for radiotherapy |
| US4963128A (en) * | 1989-03-21 | 1990-10-16 | University Of Virginia Alumni Patents Foundation | Chest tube and catheter grid for intrathoracic afterload radiotherapy |
| KR940005307B1 (en) * | 1989-04-28 | 1994-06-16 | 또낀 코포레이션 | Readily operable catheter guide wire using shape memory alloy with pseudo elasticity |
| US5147282A (en) * | 1989-05-04 | 1992-09-15 | William Kan | Irradiation loading apparatus |
| US5176617A (en) * | 1989-12-11 | 1993-01-05 | Medical Innovative Technologies R & D Limited Partnership | Use of a stent with the capability to inhibit malignant growth in a vessel such as a biliary duct |
| US5059166A (en) * | 1989-12-11 | 1991-10-22 | Medical Innovative Technologies R & D Limited Partnership | Intra-arterial stent with the capability to inhibit intimal hyperplasia |
| US5199939B1 (en) * | 1990-02-23 | 1998-08-18 | Michael D Dake | Radioactive catheter |
| US5267960A (en) * | 1990-03-19 | 1993-12-07 | Omnitron International Inc. | Tissue engaging catheter for a radioactive source wire |
| US5342283A (en) * | 1990-08-13 | 1994-08-30 | Good Roger R | Endocurietherapy |
| US6099457A (en) * | 1990-08-13 | 2000-08-08 | Endotech, Inc. | Endocurietherapy |
| US5213561A (en) * | 1990-09-06 | 1993-05-25 | Weinstein Joseph S | Method and devices for preventing restenosis after angioplasty |
| DE9017649U1 (en) * | 1990-09-08 | 1991-06-20 | Isotopen-Technik Dr. Sauerwein Gmbh, 5657 Haan, De | |
| US5092834A (en) * | 1990-10-12 | 1992-03-03 | Omnitron International, Inc. | Apparatus and method for the remote handling of highly radioactive sources in the treatment of cancer |
| US5282781A (en) * | 1990-10-25 | 1994-02-01 | Omnitron International Inc. | Source wire for localized radiation treatment of tumors |
| US5484384A (en) * | 1991-01-29 | 1996-01-16 | Med Institute, Inc. | Minimally invasive medical device for providing a radiation treatment |
| US5354257A (en) * | 1991-01-29 | 1994-10-11 | Med Institute, Inc. | Minimally invasive medical device for providing a radiation treatment |
| US5395300A (en) * | 1991-06-07 | 1995-03-07 | Omnitron International, Inc. | High dosage radioactive source |
| US5429582A (en) * | 1991-06-14 | 1995-07-04 | Williams; Jeffery A. | Tumor treatment |
| US5370685A (en) * | 1991-07-16 | 1994-12-06 | Stanford Surgical Technologies, Inc. | Endovascular aortic valve replacement |
| CN1026755C (en) * | 1991-08-17 | 1994-11-30 | 王力平 | Internal radiotherapy and apparatus thereof |
| US5302168A (en) * | 1991-09-05 | 1994-04-12 | Hess Robert L | Method and apparatus for restenosis treatment |
| AU4644193A (en) * | 1992-06-30 | 1994-01-24 | Combustion Engineering Inc. | Internal fuel rod coating |
| US5391139A (en) * | 1992-09-03 | 1995-02-21 | William Beaumont Hospital | Real time radiation treatment planning system |
| US5425720A (en) * | 1993-01-27 | 1995-06-20 | Rogalsky; Alena | Medical needle unit |
| US5405309A (en) * | 1993-04-28 | 1995-04-11 | Theragenics Corporation | X-ray emitting interstitial implants |
| US5643171A (en) * | 1993-05-04 | 1997-07-01 | Neocardia, Llc | Method and apparatus for uniform radiation treatment of vascular lumens |
| DE4315002C1 (en) * | 1993-05-06 | 1994-08-18 | Kernforschungsz Karlsruhe | Vascular implant |
| US5540659A (en) * | 1993-07-15 | 1996-07-30 | Teirstein; Paul S. | Irradiation catheter and method of use |
| US5498227A (en) * | 1993-09-15 | 1996-03-12 | Mawad; Michel E. | Retrievable, shielded radiotherapy implant |
| US5532122A (en) * | 1993-10-12 | 1996-07-02 | Biotraces, Inc. | Quantitation of gamma and x-ray emitting isotopes |
| US5503613A (en) * | 1994-01-21 | 1996-04-02 | The Trustees Of Columbia University In The City Of New York | Apparatus and method to reduce restenosis after arterial intervention |
| US5707332A (en) | 1994-01-21 | 1998-01-13 | The Trustees Of Columbia University In The City Of New York | Apparatus and method to reduce restenosis after arterial intervention |
| US5460592A (en) * | 1994-01-24 | 1995-10-24 | Amersham Holdings, Inc. | Apparatus and method for making carrier assembly for radioactive seed carrier |
| US5538494A (en) * | 1994-03-17 | 1996-07-23 | Hitachi, Ltd. | Radioactive beam irradiation method and apparatus taking movement of the irradiation area into consideration |
| US5556389A (en) * | 1994-03-31 | 1996-09-17 | Liprie; Samuel F. | Method and apparatus for treating stenosis or other constriction in a bodily conduit |
| US5618266A (en) * | 1994-03-31 | 1997-04-08 | Liprie; Samuel F. | Catheter for maneuvering radioactive source wire to site of treatment |
| US5503614A (en) * | 1994-06-08 | 1996-04-02 | Liprie; Samuel F. | Flexible source wire for radiation treatment of diseases |
| ATE170708T1 (en) * | 1994-06-10 | 1998-09-15 | Schneider Europ Gmbh | MEDICINAL DEVICE FOR THE TREATMENT OF A PART OF BODY VESSEL USING IONIZATION RADIATION |
| EP0688580B1 (en) | 1994-06-24 | 2000-10-04 | Schneider (Europe) GmbH | Medical appliance for the treatment of a portion of body vessel by ionising radiation |
| US5683345A (en) * | 1994-10-27 | 1997-11-04 | Novoste Corporation | Method and apparatus for treating a desired area in the vascular system of a patient |
| US5616114A (en) * | 1994-12-08 | 1997-04-01 | Neocardia, Llc. | Intravascular radiotherapy employing a liquid-suspended source |
| DE19600669C2 (en) | 1995-01-17 | 1997-09-25 | Christoph Dr Hehrlein | Balloon catheter to prevent re-stenosis after angioplasty, and method and semi-finished product for manufacturing a balloon catheter |
| US5653683A (en) * | 1995-02-28 | 1997-08-05 | D'andrea; Mark A. | Intracavitary catheter for use in therapeutic radiation procedures |
| US5605530A (en) * | 1995-03-23 | 1997-02-25 | Fischell; Robert E. | System for safe implantation of radioisotope stents |
| US5730698A (en) | 1995-05-09 | 1998-03-24 | Fischell; Robert E. | Balloon expandable temporary radioisotope stent system |
| ATE192346T1 (en) | 1995-06-22 | 2000-05-15 | Schneider Europ Gmbh | MEDICINAL DEVICE FOR THE TREATMENT OF A PART OF A BODY VESSEL USING IONIZATION RADIATION |
| DE19526680A1 (en) | 1995-07-21 | 1997-01-23 | Huels Chemische Werke Ag | Flexible, adaptable plastic body with single catheters or equidistantly embedded catheters or sleeves for the introduction of catheters for radiation therapy |
| US5947958A (en) | 1995-09-14 | 1999-09-07 | Conceptus, Inc. | Radiation-transmitting sheath and methods for its use |
| US5713828A (en) | 1995-11-27 | 1998-02-03 | International Brachytherapy S.A | Hollow-tube brachytherapy device |
| NL1002044C2 (en) | 1996-01-08 | 1997-07-09 | Optische Ind De Oude Delft Nv | Radioactive source that has clinically relevant beta radiation |
| US5722984A (en) | 1996-01-16 | 1998-03-03 | Iso Stent, Inc. | Antithrombogenic radioactive coating for an intravascular stent |
| US5800333A (en) | 1996-02-20 | 1998-09-01 | United States Surgical Corporation | Afterloader provided with remote control unit |
| US5916143A (en) | 1996-04-30 | 1999-06-29 | Apple; Marc G. | Brachytherapy catheter system |
| CA2202421A1 (en) | 1996-05-29 | 1997-11-29 | Joseph P. Loeffler | Radiation-emitting flow-through temporary stent |
| US5795286A (en) | 1996-08-15 | 1998-08-18 | Cathco, Inc. | Radioisotope impregnated sheet of biocompatible material for preventing scar tissue formation |
| US5820553A (en) | 1996-08-16 | 1998-10-13 | Siemens Medical Systems, Inc. | Identification system and method for radiation therapy |
| US5782740A (en) | 1996-08-29 | 1998-07-21 | Advanced Cardiovascular Systems, Inc. | Radiation dose delivery catheter with reinforcing mandrel |
| US5910101A (en) | 1996-08-29 | 1999-06-08 | Advanced Cardiovascular Systems, Inc. | Device for loading and centering a vascular radiation therapy source |
| US5947924A (en) | 1996-09-13 | 1999-09-07 | Angiorad, L.L.C. | Dilatation/centering catheter used for the treatment of stenosis or other constriction in a bodily passageway and method thereof |
| CA2266638C (en) | 1996-09-23 | 2007-05-01 | Novoste Corporation | Intraluminal radiation treatment system |
| US5924973A (en) | 1996-09-26 | 1999-07-20 | The Trustees Of Columbia University In The City Of New York | Method of treating a disease process in a luminal structure |
| US5871437A (en) | 1996-12-10 | 1999-02-16 | Inflow Dynamics, Inc. | Radioactive stent for treating blood vessels to prevent restenosis |
| US5910102A (en) | 1997-01-10 | 1999-06-08 | Scimed Life Systems, Inc. | Conversion of beta radiation to gamma radiation for intravascular radiation therapy |
| US5816259A (en) | 1997-01-13 | 1998-10-06 | Rose; Samuel | Method for the diagnosis and treatment of cancer by the accumulation of radioactive precipitates in targeted cells |
| US5782742A (en) | 1997-01-31 | 1998-07-21 | Cardiovascular Dynamics, Inc. | Radiation delivery balloon |
| US6059812A (en) | 1997-03-21 | 2000-05-09 | Schneider (Usa) Inc. | Self-expanding medical device for centering radioactive treatment sources in body vessels |
| US6033357A (en) | 1997-03-28 | 2000-03-07 | Navius Corporation | Intravascular radiation delivery device |
| US5906573A (en) | 1997-07-18 | 1999-05-25 | Radiomed Corporation | Radioactive surgical fastening devices and methods of making same |
| US6024690A (en) | 1997-07-01 | 2000-02-15 | Endosonics Corporation | Radiation source with delivery wire |
| US5919126A (en) | 1997-07-07 | 1999-07-06 | Implant Sciences Corporation | Coronary stent with a radioactive, radiopaque coating |
| US5913813A (en) | 1997-07-24 | 1999-06-22 | Proxima Therapeutics, Inc. | Double-wall balloon catheter for treatment of proliferative tissue |
| US5816999A (en) | 1997-07-24 | 1998-10-06 | Bischoff; Jeffrey | Flexible catheter for the delivery of ionizing radiation to the interior of a living body |
| US6010445A (en) | 1997-09-11 | 2000-01-04 | Implant Sciences Corporation | Radioactive medical device and process |
| US5938582A (en) | 1997-09-26 | 1999-08-17 | Medtronic, Inc. | Radiation delivery centering catheter |
| EP0904799A1 (en) | 1997-09-26 | 1999-03-31 | Schneider (Europe) GmbH | Dilation catheter with balloon having a determined ration of balloon volume and square surface of the inflation lumen |
| DE59708672D1 (en) | 1997-09-26 | 2002-12-12 | Schneider Europ Gmbh Buelach | Balloon catheter inflated with carbon dioxide for radiotherapy |
| US6030333A (en) | 1997-10-24 | 2000-02-29 | Radiomed Corporation | Implantable radiotherapy device |
| US5957829A (en) | 1997-12-17 | 1999-09-28 | Advanced Cardiovascular Systems, Inc. | Apparatus and method for radiotherapy using a radioactive source wire having a magnetic insert |
| KR100228187B1 (en) | 1997-12-24 | 1999-11-01 | 김성년 | A radioactive ballon used in balloon dilatation catherer and process for preparation thereof |
| DE19758234C2 (en) | 1997-12-30 | 2003-04-17 | Anwer Puthawala | Use of a radioactive catheter |
| US5997462A (en) | 1998-01-08 | 1999-12-07 | Delft Instruments Intellectual Property B.V. | Method and apparatus for treating a blood vessel lesion |
| US5961439A (en) | 1998-05-06 | 1999-10-05 | United States Surgical Corporation | Device and method for radiation therapy |
| US5997463A (en) | 1998-03-26 | 1999-12-07 | North American Scientific | Laser welded brachytherapy source and method of making the same |
| US6013019A (en) | 1998-04-06 | 2000-01-11 | Isostent, Inc. | Temporary radioisotope stent |
| DE19825563C1 (en) | 1998-06-08 | 1999-12-02 | Siemens Ag | Catheter X=ray tube |
| DE19826000C1 (en) | 1998-06-10 | 1999-12-30 | Siemens Ag | Catheter assembly for intracorporal X-ray therapeutic treatment |
| DE19825999A1 (en) | 1998-06-10 | 1999-12-23 | Siemens Ag | System for intracorporeal and intraluminal X-ray therapy |
| DE19829447A1 (en) | 1998-07-01 | 2000-01-05 | Siemens Ag | X-ray radiation catheter for treatment of vascular wall |
-
1995
- 1995-12-05 DE DE69530302T patent/DE69530302T2/en not_active Expired - Lifetime
- 1995-12-05 EP EP95119124A patent/EP0778051B1/en not_active Expired - Lifetime
- 1995-12-05 AT AT95119124T patent/ATE236683T1/en not_active IP Right Cessation
-
1996
- 1996-10-15 AU AU70204/96A patent/AU700595B2/en not_active Ceased
- 1996-10-21 CA CA002188351A patent/CA2188351C/en not_active Expired - Fee Related
- 1996-10-30 US US08/739,649 patent/US6146322A/en not_active Expired - Lifetime
- 1996-12-03 JP JP32269496A patent/JP3188896B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP3188896B2 (en) | 2001-07-16 |
| EP0778051B1 (en) | 2003-04-09 |
| DE69530302T2 (en) | 2004-01-29 |
| ATE236683T1 (en) | 2003-04-15 |
| AU700595B2 (en) | 1999-01-07 |
| US6146322A (en) | 2000-11-14 |
| AU7020496A (en) | 1997-06-12 |
| EP0778051A1 (en) | 1997-06-11 |
| CA2188351A1 (en) | 1997-06-06 |
| DE69530302D1 (en) | 2003-05-15 |
| JPH09173481A (en) | 1997-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2188351C (en) | Filament for irradiating a living body and method for producing a filament for irradiating a living body | |
| JP2908243B2 (en) | Medical devices for treating parts of blood vessels | |
| US6505392B1 (en) | Process for manufacturing a radioactive source wire for irradiating diseased tissue | |
| EP0765175B1 (en) | Flexible source wire for radiation treatment | |
| US5910102A (en) | Conversion of beta radiation to gamma radiation for intravascular radiation therapy | |
| EP0873157A1 (en) | Improved flexible source wire for localized internal irradiation of tissue | |
| WO2000009211A9 (en) | Improved radioactive therapeutic seeds and methods of making the same | |
| EP1066087A1 (en) | Laser welded brachytherapy source and method of making the same | |
| CA2385369C (en) | Radiation source for endovascular radiation treatment in form of a wire | |
| US6400796B1 (en) | X-ray emitting sources and uses thereof | |
| EP0997163B1 (en) | A method for producing a coiled body for radioactive irradiation | |
| AU7139600A (en) | Integral capsule sourcewire and method of making | |
| US20010055359A1 (en) | Flexible source wire for radiation | |
| AU5184300A (en) | Improved flexible source wire for localized internal irradiation of tissue |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |